Analysis looks at role type of valve plays in patient outcomes post-TAVR
(Society for Cardiovascular Angiography and Interventions) Results from 'Impact of valve design and bivalirudin vs. unfractionated heparin for anticoagulation in transcatheter aortic valve replacement: Results from the BRAVO-3 trial' were presented today as a late-breaking clinical trial at the Society for CardiovascularAngiography and Interventions (SCAI) 2017 Scientific Sessions in New Orleans.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Angiography | Angiomax | Cardiology | Cardiovascular | Clinical Trials | Heart | Heart Valve Surgery | International Medicine & Public Health